StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Sunday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.06.

OncoCyte Stock Performance

Shares of OncoCyte stock opened at $3.10 on Friday. OncoCyte has a 1 year low of $2.08 and a 1 year high of $4.34. The company has a 50-day moving average of $3.08 and a 200 day moving average of $2.95.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The company had revenue of $0.10 million for the quarter.

Insider Activity at OncoCyte

In other news, CFO Andrea S. James acquired 33,670 shares of OncoCyte stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the purchase, the chief financial officer now directly owns 33,670 shares in the company, valued at approximately $99,999.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other OncoCyte news, CFO Andrea S. James bought 33,670 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now directly owns 6,244,405 shares in the company, valued at $18,420,994.75. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 1.58% of the stock is currently owned by corporate insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.